Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Olpasiran in Subjects With Hepatic Impairment
NCT05481411Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of olpasiran in elevated lipoprotein(a) (Lp(a)) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration of Olpasiran at Day 29, Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration of Olpasiran at Day 29 and 1 more. Started Sep 2022; status: completed.
02
Drugs
olpasiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05481411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481411.